A novel function for lysyl oxidase in pluripotent mesenchymal cell proliferation and relevance to inflammation-associated osteopenia

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Khosravi, Roozbeh ^a   Sodek, Katharine L ^a   Xu, Wan Peng ^a   Bais, Manish V ^a   Saxena, Debashree ^a   Faibish, Michael ^a   Trackman, Philip C ^a  

^a BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LYSYL OXIDASE LIKE 1 PROTEIN; MESSENGER RNA; MICRORNA; MICRORNA 203; OXIDOREDUCTASE; PROTEIN LYSINE 6 OXIDASE; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WNT3A PROTEIN; CULTURE MEDIUM; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE DEVELOPMENT; BONE MARROW CELL; CARTILAGE CELL; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; ENZYME ACTIVITY; ENZYME INDUCTION; EXTRACELLULAR MATRIX; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOPENIA; PROTEIN EXPRESSION; RAT; STROMA CELL; TRANSCRIPTION REGULATION; WNT SIGNALING PATHWAY; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE DISEASES, METABOLIC; C57BL MOUSE; CELL CULTURE; CELL DIFFERENTIATION; CULTURE MEDIUM; CYTOLOGY; DRUG EFFECTS; ENZYMOLOGY; GENETICS; INFLAMMATION; MESENCHYMAL STROMA CELL; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHARMACOLOGY; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; BASE SEQUENCE; BONE DISEASES, METABOLIC; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; DOWN-REGULATION; INFLAMMATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL; MICRORNAS; MOLECULAR SEQUENCE DATA; OSTEOBLASTS; OSTEOGENESIS; PROTEIN-LYSINE 6-OXIDASE; RATS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; WNT3A PROTEIN;

EID: 84903516822     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100669     Document Type: Article

References (43)

1. Bouillon R (1991) Diabetic bone disease. Calcif Tissue Int 49: 155-160.
2. Merlotti D, Gennari L, Dotta F, Lauro D, Nuti R (2010) Mechanisms of impaired bone strength in type 1 and 2 diabetes. Nutr Metab Cardiovasc Dis 20: 683-690.
3. Saito M, Fujii K, Mori Y, Marumo K (2006) Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int 17: 1514-1523. (Pubitemid 44387486)
4. Oxlund H, Mosekilde L, Ortoft G (1996) Reduced concentration of collagen reducible cross links in human trabecular bone with respect to age and osteoporosis. Bone 19: 479-484.
5. Saito M, Marumo K (2013) Bone quality in diabetes. Front Endocrinol (Lausanne) 4: 72.
6. Graves DT, Liu R, Alikhani M, Al-Mashat H, Trackman PC (2006) Diabetes-enhanced inflammation and apoptosis-impact on periodontal pathology. J Dent Res 85: 15-21. (Pubitemid 43827757)
7. Cagnetta V, Patella V (2012) The role of the immune system in the physiopathology of osteoporosis. Clin Cases Miner Bone Metab 9: 85-88.
8. Rauner M, Sipos W, Thiele S, Pietschmann P (2013) Advances in osteoimmunology: pathophysiologic concepts and treatment opportunities. Int Arch Allergy Immunol 160: 114-125.
9. Khosla S, Westendorf JJ, Oursler MJ (2008) Building bone to reverse osteoporosis and repair fractures. J Clin Invest 118: 421-428. (Pubitemid 351206529)
10. Monroe DG, McGee-Lawrence ME, Oursler MJ, Westendorf JJ (2012) Update on Wnt signaling in bone cell biology and bone disease. Gene 492: 1-18.
11. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, et al. (2001) LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107: 513-523. (Pubitemid 33152786)
12. Almeida M, Han L, Martin-Millan M, O'Brien CA, Manolagas SC (2007) Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting beta-catenin from T cell factor- to forkhead box O-mediated transcription. J Biol Chem 282: 27298-27305. (Pubitemid 47501978)
13. Alikhani M, Alikhani Z, Graves DT (2005) FOXO1 functions as a master switch that regulates gene expression necessary for tumor necrosis factor-induced fibroblast apoptosis. J Biol Chem 280: 12096-12102.
14. Alikhani M, Maclellan C, Raptis M, Vora S, Trackman P, et al. (2006) Advanced Glycation Endproducts Induce Apoptosis In Fibroblasts Through Activation of ROS, MAP kinases and FOXO1 Transcription Factor. Am J Physiol Cell Physiol.
15. Manolagas SC, Almeida M (2007) Gone with the Wnts: {beta}-catenin, TCF, FOXO, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Mol Endocrinol 21: 2605-2614. (Pubitemid 350035144)
16. Jackson A, Vayssiere B, Garcia T, Newell W, Baron R, et al. (2005) Gene array analysis of Wnt-regulated genes in C3H10T1/2 cells. Bone 36: 585-598. (Pubitemid 40602252)
17. Oxlund H, Barckman M, Ortoft G, Andreassen TT (1995) Reduced concentrations of collagen cross-links are associated with reduced strength of bone. Bone 17: 365s-371s.
18. Kagan HM, Trackman PC (1991) Properties and function of lysyl oxidase. Am J Respir Cell Mol Biol 5: 206-210.
19. Choi SS, Cha BY, Lee YS, Yonezawa T, Teruya T, et al. (2009) Magnolol enhances adipocyte differentiation and glucose uptake in 3T3-L1 cells. Life Sci 84: 908-914.
20. Huang H, Song TJ, Li X, Hu L, He Q, et al. (2009) BMP signaling pathway is required for commitment of C3H10T1/2 pluripotent stem cells to the adipocyte lineage. Proc Natl Acad Sci U S A 106: 12670-12675.
21. Yeh LC, Lee JC (2010) Effects of cartilage-derived morphogenetic protein-3 on the expression of chondrogenic and osteoblastic markers in the pluripotent mesenchymal C3H10T1/2 cell line. Growth Factors 28: 117-128.
22. Vora SR, Palamakumbura AH, Mitsi M, Guo Y, Pischon N, et al. (2010) Lysyl oxidase propeptide inhibits FGF-2-induced signaling and proliferation of osteoblasts. J Biol Chem 285: 7384-7393.
23. Reynaud C, Gleyzal C, Jourdan-Le Saux C, Sommer P (1999) Comparative functional study of the lysyl oxidase promoter in fibroblasts, Ras-transformed fibroblasts, myofibroblasts and smooth muscle cells. Cell Mol Biol (Noisy-legrand) 45: 1237-1247.
24. Jourdan-Le Saux C, Gleyzal C, Raccurt M, Sommer P (1997) Functional analysis of the lysyl oxidase promoter in myofibroblast-like clones of 3T6 fibroblast. J Cell Biochem 64: 328-341. (Pubitemid 27065445)
25. Brannon M, Gomperts M, Sumoy L, Moon RT, Kimelman D (1997) A beta-catenin/XTcf-3 complex binds to the siamois promoter to regulate dorsal axis specification in Xenopus. Genes Dev 11: 2359-2370. (Pubitemid 27408533)
26. Guo W, Keckesova Z, Donaher JL, Shibue T, Tischler V, et al. (2012) Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 148: 1015-1028.
27. Khosravi R, Sodek KL, Faibish M, Trackman PC (2014) Collagen advanced glycation inhibits its Discoidin Domain Receptor 2 (DDR2)-mediated induction of lysyl oxidase in osteoblasts. Bone 58: 33-41.
28. Bais MV, Ozdener GB, Sonenshein GE, Trackman PC (2014) Effects of tumor suppressor lysyl oxidase propeptide on prostate cancer xenograft growth and its direct interactions with DNA repair pathways. Oncogene; In Press.
29. Nusse R, Varmus H (2012) Three decades of Wnts: a personal perspective on how a scientific field developed. EMBO J 31: 2670-2684.
30. Semenov MV, Tamai K, Brott BK, Kuhl M, Sokol S, et al. (2001) Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6. Curr Biol 11: 951-961. (Pubitemid 32589186)
31. Semenov M, Tamai K, He X (2005) SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 280: 26770-26775. (Pubitemid 41040710)
32. Pischon N, Maki JM, Weisshaupt P, Heng N, Palamakumbura AH, et al. (2009) Lysyl oxidase (lox) gene deficiency affects osteoblastic phenotype. Calcif Tissue Int 85: 119-126.
33. Liu R, Bal HS, Desta T, Behl Y, Graves DT (2006) Tumor necrosis factor-alpha mediates diabetes-enhanced apoptosis of matrix-producing cells and impairs diabetic healing. Am J Pathol 168: 757-764. (Pubitemid 43327728)
34. Essers MA, de Vries-Smits LM, Barker N, Polderman PE, Burgering BM, et al. (2005) Functional interaction between beta-catenin and FOXO in oxidative stress signaling. Science 308: 1181-1184. (Pubitemid 40696437)
35. Betel D, Koppal A, Agius P, Sander C, Leslie C (2010) Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol 11: R90.
36. Bouillon R (1991) Diabetic bone disease. Calcif Tissue Int 49: 155-160.
37. Lucero HA, Ravid K, Grimsby JL, Rich CB, DiCamillo SJ, et al. (2008) Lysyl oxidase oxidizes cell membrane proteins and enhances the chemotactic response of vascular smooth muscle cells. J Biol Chem 283: 24103-24117.
38. Baker AM, Bird D, Lang G, Cox TR, Erler JT (2013) Lysyl oxidase enzymatic function increases stiffness to drive colorectal cancer progression through FAK. Oncogene 32: 1863-1868.
39. Payne SL, Fogelgren B, Hess AR, Seftor EA, Wiley EL, et al. (2005) Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism. Cancer Res 65: 11429-11436. (Pubitemid 41821700)
40. Atsawasuwan P, Mochida Y, Katafuchi M, Kaku M, Fong KS, et al. (2008) Lysyl oxidase binds transforming growth factor-beta and regulates its signaling via amine oxidase activity. J Biol Chem 283: 34229-34240.
41. Li W, Nugent MA, Zhao Y, Chau AN, Li SJ, et al. (2003) Lysyl oxidase oxidizes basic fibroblast growth factor and inactivates its mitogenic potential. J Cell Biochem 88: 152-164. (Pubitemid 36015085)
42. Nakerakanti S, Trojanowska M (2012) The Role of TGF-beta Receptors in Fibrosis. Open Rheumatol J 6: 156-162.
43. Goetz R, Mohammadi M (2013) Exploring mechanisms of FGF signalling through the lens of structural biology. Nat Rev Mol Cell Biol 14: 166-180.